Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

106235 reported adverse events

Drugs of this class: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE LAMIVUDINE LAMIVUDINE AND ZIDOVUDINE EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE ZIDOVUDINE ABACAVIR AND LAMIVUDINE EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE EMTRICITABINE EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE ABACAVIR , LAMIVUDINE AND ZIDOVUDINE

These side effects are most commonly reported by patients taking drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class:

#	Side effect	Count
0	BONE DENSITY DECREASED	18618
1	CHRONIC KIDNEY DISEASE	11219
2	RENAL FAILURE	9920
3	OSTEONECROSIS	9789
4	BONE LOSS	9514
5	TOOTH LOSS	8881
6	RENAL INJURY	8870
7	PAIN	8612
8	MULTIPLE FRACTURES	8552
9	OSTEOPOROSIS	8156

See all common reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	BONE DEMINERALISATION	409	0.9170
1	CSF HIV ESCAPE SYNDROME	113	0.9040
2	PINEALOBLASTOMA	79	0.8778
3	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA	94	0.8545
4	SKELETAL INJURY	7768	0.8200
5	BONE LOSS	9514	0.7733
6	BLOOD HIV RNA INCREASED	756	0.7146
7	IMMUNE RECONSTITUTION SYNDROME	917	0.7098
8	HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION	147	0.7067
9	BONE DENSITY DECREASED	18618	0.7047

See all enriched reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]